MaxCyte, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving MaxCyte, Inc. now
Current reporting with the operating signal separated from the noise.
MaxCyte, Inc: MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to Profitability
Investors are testing whether MaxCyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.With 66% institutional ownership, MaxCyte, Inc. (LON:MXCT) is a favorite amongst the big guns
The story matters when it changes MaxCyte, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MaxCyte, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results Release Date and Earnings Call Details
Investors are testing whether MaxCyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MaxCyte, Inc. Acquires SeQure Dx to Enhance Cell and Gene Therapy Solutions
The story matters when it changes MaxCyte, Inc.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
Investors are testing whether MaxCyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.MaxCyte, Inc: MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance
Investors are testing whether MaxCyte, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest MXCT filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
MaxCyte, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →